플랫폼과 전략
논문 &학회발표
Home플랫폼과 전략논문 &학회발표
| NO | 과제 | 학회 | 발표제목 | 발표자료 |
|---|---|---|---|---|
| 10 | ABL105 | ESMO2021 | ESMO2021 / A novel HER2/4-1BB bispecific antibody, YH32367 (ABL105) exerts significant anti-tumor effects through tumor-directed T cell activation |
|
| 9 | 4-1BB Platform | AACR 2021 | AACR 2021 / A novel anti-CD137 antibody recognizing the membrane-proximal CD137 domain elicits potent anti-tumor T cell activity in a bispecific antibody format |
|
| 8 | ABL501 | AACR2021 | AACR2021 / ABL501 (PD-L1xLAG-3), a bispecific antibody promotes enhanced human T cell activation through targeting simultaneously two immune checkpoint inhibitors, LAG-3 and PD-L1 |
|
| 7 | Grabody T | AACR2021 | AACR2021 / A novel anti-CD137 antibody recognizing the membrane-proximal CD137 domain elicits potent anti-tumor T cell activity in a bispecific antibody format |
|
| 6 | 4-1BB Platform | AACR 2020 | AACR 2020 / B7-H3-targeted 4-1BB activation potentiates CD8 T cell-dependent antitumor immunity without systemic toxicity |
|
| 5 | ABL111 | AACR 2020 | AACR 2020 / Claudin 18.2 x 4-1BB bispecific antibody induced potent tumor inhibition through tumor-specific 4-1BB activation |
|
| 4 | ABL001 | PEPTALK 2020 | PEPTALK 2020 / Summary of phase 1a dose escalation clinical study data for dual angiogenic bispecific antibody targeting VEGF and DLL4 (ABL001/NOV1501/TR009) in patients with previously treated solid tumors |
|
| 3 | ABL503 | PEGS 2019 | PEGS 2019 / The PD-L1 x 4-1BB Bispecific Antibody ABL503 Shows Potent Anti-Tumor Effect through Tumor-Directed T Cell Activation |
|
| 2 | ABL001 | ASCO 2019 | ASCO 2019 / Phase 1a study results investigating the safety and preliminary efficacy of ABL001 (NOV1501), a bispecific antibody targeting VEGF and DLL4 in metastatic gastrointesinal (GI) cancer |
|
| 1 | ABL001 | PEGS 2017 | PEGS 2017 / Preclinical development of an anti-cancer bispecific antibody targeting VEGF and DLL4, ABL001 |
|
-
ESMO2021 / A novel HER2/4-1BB bispecific antibody, YH32367 (ABL105) exerts significant anti-tumor effects through tumor-directed T cell activation
-
AACR 2021 / A novel anti-CD137 antibody recognizing the membrane-proximal CD137 domain elicits potent anti-tumor T cell activity in a bispecific antibody format
-
AACR2021 / ABL501 (PD-L1xLAG-3), a bispecific antibody promotes enhanced human T cell activation through targeting simultaneously two immune checkpoint inhibitors, LAG-3 and PD-L1
-
AACR2021 / A novel anti-CD137 antibody recognizing the membrane-proximal CD137 domain elicits potent anti-tumor T cell activity in a bispecific antibody format
-
AACR 2020 / B7-H3-targeted 4-1BB activation potentiates CD8 T cell-dependent antitumor immunity without systemic toxicity
-
AACR 2020 / Claudin 18.2 x 4-1BB bispecific antibody induced potent tumor inhibition through tumor-specific 4-1BB activation
-
PEPTALK 2020 / Summary of phase 1a dose escalation clinical study data for dual angiogenic bispecific antibody targeting VEGF and DLL4 (ABL001/NOV1501/TR009) in patients with previously treated solid tumors
-
PEGS 2019 / The PD-L1 x 4-1BB Bispecific Antibody ABL503 Shows Potent Anti-Tumor Effect through Tumor-Directed T Cell Activation
-
ASCO 2019 / Phase 1a study results investigating the safety and preliminary efficacy of ABL001 (NOV1501), a bispecific antibody targeting VEGF and DLL4 in metastatic gastrointesinal (GI) cancer
-
PEGS 2017 / Preclinical development of an anti-cancer bispecific antibody targeting VEGF and DLL4, ABL001